No Prescription |
 |
 | ||
|
Ol Vamlo Generic Olmesartan |
|
| ||
No Prescription » Prescription Drugs 12 » Ol Vamlo Generic Olmesartan Ol-Vamlo is combination medications to treat high blood pressure and chest pain. Olmesartan is in a class of medications called angiotensin II receptor antagonists. It works by blocking the action of certain chemicals that tighten the blood vessels so blood flows more smoothly.Amlodipine is in a class of medications called calcium channel blockers. It lowers blood pressure by relaxing the blood vessels so the heart does not have to pump as hard. It controls chest pain by increasing the supply of blood to the heart. If taken regularly amlodipine controls chest pain but it does not stop chest pain once it starts. Your doctor may prescribe a different medication to take when you have chest pain. Buy Ol Vamlo Generic Olmesartan and other Prescription Drugs 12 products online at Medstore. Buy Online at Medstore - Click Here!
About Ol Vamlo Generic Olmesartan: Product Type: Prescription Drugs 12 Ol-Vamlo (Generic Olmesartan/Amlodipine) Ol-Vamlo (Generic Olmesartan/Amlodipine) Generic Olmesartan/Amlodipine 20/5mg Generic Olmesartan/Amlodipine Ol-Vamlo
View more Prescription Drugs 12 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
